One of the more serious issues with rapamycin and rapalogs is the induction of Akt and ERK signaling in cancer cells (Figure 1) that is caused by activation of mTORC2 due to mTORC1 inhibition, as discussed previously [111,147] (for further details, see review [148]). The gene discussed is AKT1; the disease is cancer.